Shanghai Pharmaceuticals Holding Stock Net Income
| 601607 Stock | 21.93 0.51 2.38% |
Shanghai Pharmaceuticals Holding fundamentals help investors to digest information that contributes to Shanghai Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Shanghai Stock. The fundamental analysis module provides a way to measure Shanghai Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Income Applicable To Common Shares | 5.9 B | 6.2 B | |
| Net Income | 3.8 B | 2.2 B | |
| Net Income From Continuing Ops | 5.2 B | 5.4 B |
Shanghai | Net Income |
Shanghai Pharmaceuticals Holding Company Net Income Analysis
Shanghai Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Shanghai Pharmaceuticals Net Income | 3.77 B |
Most of Shanghai Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Shanghai Operating Income
Operating Income |
|
Based on the recorded statements, Shanghai Pharmaceuticals Holding reported net income of 3.77 B. This is much higher than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The net income for all China stocks is notably lower than that of the firm.
Shanghai Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shanghai Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Shanghai Pharmaceuticals by comparing valuation metrics of similar companies.Shanghai Pharmaceuticals is currently under evaluation in net income category among its peers.
Shanghai Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Shanghai Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Shanghai Pharmaceuticals' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Shanghai Fundamentals
| Return On Equity | 0.0641 | ||||
| Return On Asset | 0.0241 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 80.19 B | ||||
| Shares Outstanding | 2.79 B | ||||
| Shares Owned By Insiders | 65.61 % | ||||
| Shares Owned By Institutions | 13.26 % | ||||
| Price To Book | 1.15 X | ||||
| Price To Sales | 0.27 X | ||||
| Revenue | 260.3 B | ||||
| Gross Profit | 28.41 B | ||||
| EBITDA | 9.62 B | ||||
| Net Income | 3.77 B | ||||
| Total Debt | 35.56 B | ||||
| Book Value Per Share | 19.13 X | ||||
| Cash Flow From Operations | 5.23 B | ||||
| Earnings Per Share | 1.08 X | ||||
| Price To Earnings To Growth | 10.62 X | ||||
| Target Price | 21.44 | ||||
| Number Of Employees | 48.16 K | ||||
| Beta | 0.32 | ||||
| Market Capitalization | 72.7 B | ||||
| Total Asset | 211.97 B | ||||
| Retained Earnings | 33.82 B | ||||
| Working Capital | 40.06 B | ||||
| Net Asset | 211.97 B | ||||
| Last Dividend Paid | 0.41 |
About Shanghai Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Pharmaceuticals financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Pharmaceuticals security.